The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
This article reviews the initial experience with chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) and outlines some of the ongoing clinical trials in this area. In addition, the authors outline current knowledge on outcomes of patients treated with taxane-based chemotherapy on retrospective analysis of randomized trials. These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials.
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD, USA. eisenma@jhmi.edu
Mario A
MA
Eisenberger
Emmanuel S
ES
Antonarakis
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003603:Cytotoxins / Q000627:therapeutic use*; D018450:Disease Progression; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D004961:Estramustine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000556:secondary*; D043823:Taxoids / Q000008:administration & dosage* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D003603:Cytotoxins; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; C552428:cabazitaxel; D008942:Mitoxantrone